Interactions between Buspirone and Sparsentan

busPIRone has a moderate potential interaction with Alcoholism.

In human and animal studies, buspirone has not shown potential for abuse or diversion, and there is no evidence that it causes tolerance or physical and psychological dependence. However, since it is a CNS-active drug, the manufacturers recommend that therapy with buspirone be administered cautiously in addiction-prone individuals, such as those with a history of alcohol or substance abuse. It may be prudent to refrain from dispensing large quantities of medication to these patients.

busPIRone has a major potential interaction with Depression.

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics. Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations. These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation. Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

busPIRone has a moderate potential interaction with Drug Dependence.

In human and animal studies, buspirone has not shown potential for abuse or diversion, and there is no evidence that it causes tolerance or physical and psychological dependence. However, since it is a CNS-active drug, the manufacturers recommend that therapy with buspirone be administered cautiously in addiction-prone individuals, such as those with a history of alcohol or substance abuse. It may be prudent to refrain from dispensing large quantities of medication to these patients.

busPIRone has a moderate potential interaction with Glaucoma/Intraocular Hypertension.

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.

Sparsentan has a moderate potential interaction with Heart Failure.

Sparsentan has not been studied in patients with heart failure. Fluid retention may occur with endothelin receptor antagonists, including this drug. If fluid retention develops, modifications such as dose adjustment of sparsentan or diuretics may be required.

Sparsentan has a moderate potential interaction with Hypotension.

Sparsentan may cause hypotension. In patients at risk for hypotension, consider eliminating or adjusting other antihypertensive medications and maintaining appropriate volume status.

busPIRone has a major potential interaction with Liver Disease.

Buspirone is primarily metabolized by the liver and subsequently eliminated by the kidney. In one study, steady-state area under the plasma concentration-time curve (AUC) of buspirone increased 13-fold in subjects with hepatic impairment and 4-fold in those with renal impairment compared to healthy subjects. Therapy with buspirone is not recommended in the presence of significantly impaired hepatic or renal function.

Sparsentan has a major potential interaction with Liver Disease.

Endothelin receptor antagonists (ERAs) have been associated with aminotransferase elevations, hepatotoxicity, and cases of liver failure. Hepatic function should be assessed before treatment initiation and closely monitored during treatment. Therapy should be discontinued if aminotransferase elevations are accompanied by increases in bilirubin, or clinical symptoms of hepatotoxicity such as nausea, vomiting, fever, abdominal pain or jaundice. Treatment should be avoided in patients with elevated aminotransferases at baseline as monitoring for hepatotoxicity may be more difficult. In general, the use of ERAs is not recommended for patients with moderate to severe hepatic impairment.

busPIRone has a moderate potential interaction with Liver Disease.

In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly. Laboratory testing is recommended prior and during treatment.

busPIRone has a major potential interaction with Renal Dysfunction.

Buspirone is primarily metabolized by the liver and subsequently eliminated by the kidney. In one study, steady-state area under the plasma concentration-time curve (AUC) of buspirone increased 13-fold in subjects with hepatic impairment and 4-fold in those with renal impairment compared to healthy subjects. Therapy with buspirone is not recommended in the presence of significantly impaired hepatic or renal function.

Sparsentan has a moderate potential interaction with Renal Dysfunction.

Sparsentan is associated with a risk of renal impairment, including acute kidney injury, and hyperkalemia. Patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion may be at particular risk of developing acute kidney injury or hyperkalemia. Monitor renal function periodically.

busPIRone has a moderate potential interaction with Urinary Retention.

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.